Daily2d
Lupin bags tentative USFDA nod for Raltegravir Tablets for HIV-1 infection
600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and may be eligible to receive a 180 ...
Canada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to ...
Pharmabiz4d
Lupin receives US FDA tentative approval for raltegravir tablets, USP
600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and may be eligible to receive a 180-day exclusivity. This product will be manufactured at Lupin’s Nagpur ...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...
EurekAlert!5d
Reconstruction of historical seasonal influenza patterns and individual lifetime infection histories in humans based on antibody profiles
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing ...